0
0

International Pharmaceutical Transparency Act of 2019

10/28/2022, 1:46 AM

Congressional Summary of HR 5381

International Pharmaceutical Transparency Act of 2019

This bill prohibits the sale of a drug if its label fails to list the country of origin of each of the drug's active ingredients.

Current Status of Bill HR 5381

Bill HR 5381 is currently in the status of Bill Introduced since December 10, 2019. Bill HR 5381 was introduced during Congress 116 and was introduced to the House on December 10, 2019.  Bill HR 5381's most recent activity was Referred to the Subcommittee on Health. as of December 11, 2019

Bipartisan Support of Bill HR 5381

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5381

Primary Policy Focus

Health

Potential Impact Areas

- Consumer affairs
- Drug safety, medical device, and laboratory regulation
- Prescription drugs

Alternate Title(s) of Bill HR 5381

International Pharmaceutical Transparency Act of 2019
To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug to list the country of origin of each of the drug's active ingredients.
International Pharmaceutical Transparency Act of 2019

Comments